| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,491,933 ) |
| | 2025 | 2025 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01MH131480 | The changing face of HIV in the era of COVID-19: Maximising HIV incidence reduction through dynamic targeting of current and future distributions of acquisition risk. | 000 | 3 | NIH | 1/23/2025 | $441,781 |
| | 2025 | 2025 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | UM1AI069521 | Stellenbosch University Clinical Trials Unit | 000 | 19 | NIH | 11/18/2024 | $547,252 |
| | 2025 | 2025 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | UM1AI069521 | Stellenbosch University Clinical Trials Unit | 000 | 19 | NIH | 11/18/2024 | $200,500 |
| | 2025 | 2025 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW012758 | Next Generation Training in HIV Research: Immunity in the First 1000 days in mother-infant dyads (TIGRIS) | 000 | 2 | NIH | 12/11/2024 | $185,734 |
| | 2025 | 2025 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW012758 | Next Generation Training in HIV Research: Immunity in the First 1000 days in mother-infant dyads (TIGRIS) | 000 | 2 | NIH | 12/11/2024 | $116,666 |
| | 2025 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | U01AI152075 | Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | 000 | 4 | NIH | 10/11/2024 | $0 |
| | 2025 | 2022 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI136836 | Inhibitors of CoA biosynthesis as novel antitubercular and antistaphylococcal agents | 000 | 5 | NIH | 4/23/2025 | $0 |
| | 2025 | 2022 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R21TW012185 | Study of Metformin to reduce Cerebrovascular Dysfunction in South African patients with HIV and Metabolic Syndrome: A Phase II Pilot Trial. SMART | 000 | 2 | NIH | 10/28/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $8,642,868 ) (Continued on the next page) |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | U01AI152075 | Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | 002 | 4 | NIH | 4/19/2024 | $150,000 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012849 | Cardiovascular magnetic resonance assessment of subclinicalcardiovascular abnormalities before and after the initiation of antiretroviral therapy in HIV-infected South Africans | 001 | 1 | NIH | 9/20/2024 | $100,558 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012849 | Cardiovascular magnetic resonance assessment of subclinicalcardiovascular abnormalities before and after the initiation of antiretroviral therapy in HIV-infected South Africans | 001 | 1 | NIH | 9/20/2024 | -$100,558 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012849 | Cardiovascular magnetic resonance assessment of subclinicalcardiovascular abnormalities before and after the initiation of antiretroviral therapy in HIV-infected South Africans | 000 | 1 | NIH | 9/2/2024 | $1 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012849 | Cardiovascular magnetic resonance assessment of subclinicalcardiovascular abnormalities before and after the initiation of antiretroviral therapy in HIV-infected South Africans | 000 | 1 | NIH | 9/2/2024 | $100,558 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | U01MH127704 | Research for Ethical Data Science in Southern Africa (REDSSA) | 000 | 4 | NIH | 8/12/2024 | $376,418 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012786 | Mycobacterial Epigenetics: Investigating the impact of DNA methylation on antibiotic tolerance and persistence | 000 | 1 | NIH | 8/23/2024 | $106,160 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | UM1AI069521 | Stellenbosch University Clinical Trials Unit | 001 | 18 | NIH | 7/2/2024 | $364,007 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | UM1AI069521 | Stellenbosch University Clinical Trials Unit | 001 | 18 | NIH | 7/2/2024 | $293,866 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | UM1AI069521 | Stellenbosch University Clinical Trials Unit | 000 | 18 | NIH | 11/7/2023 | $657,875 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01MH131480 | The changing face of HIV in the era of COVID-19: Maximising HIV incidence reduction through dynamic targeting of current and future distributions of acquisition risk. | 002 | 2 | NIH | 8/21/2024 | $0 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01MH131480 | The changing face of HIV in the era of COVID-19: Maximising HIV incidence reduction through dynamic targeting of current and future distributions of acquisition risk. | 001 | 2 | NIH | 7/5/2024 | $50,321 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01MH131480 | The changing face of HIV in the era of COVID-19: Maximising HIV incidence reduction through dynamic targeting of current and future distributions of acquisition risk. | 000 | 2 | NIH | 12/15/2023 | $452,894 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R33HD103093 | CHERISH (Children HIV Exposed Uninfected Research to Inform Survival and Health) | 003 | 4 | NIH | 8/12/2024 | $5,209 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R33HD103093 | CHERISH (Children HIV Exposed Uninfected Research to Inform Survival and Health) | 002 | 4 | NIH | 6/14/2024 | $515,718 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW012467 | African Tuberculosis Bioinformatics Training Program | 001 | 1 | NIH | 6/12/2024 | -$50,000 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW012467 | African Tuberculosis Bioinformatics Training Program | 001 | 1 | NIH | 6/12/2024 | $50,000 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW012467 | African Tuberculosis Bioinformatics Training Program | 000 | 1 | NIH | 3/19/2024 | $248,483 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012591 | Development of a Next-generation Rapid Phenotypic Assay for Drug-Resistant M. tuberculosis | 000 | 2 | NIH | 4/4/2024 | $106,178 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW011006 | Interdisciplinary and multi-level approach to estimate the disease burden and outcomes of childhood tuberculous meningitis. | 000 | 5 | NIH | 12/25/2023 | $113,400 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01HD107063 | Understanding ischemia in children with tuberculous meningitis (iThemba) | 000 | 3 | NIH | 7/11/2024 | $409,956 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI175235 | Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID) | 002 | 2 | NIH | 7/19/2024 | $0 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI175235 | Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID) | 002 | 2 | NIH | 7/19/2024 | $0 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI175235 | Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID) | 001 | 2 | NIH | 3/19/2024 | $556,256 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI175235 | Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID) | 001 | 2 | NIH | 3/19/2024 | $250,000 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01MH133488 | Harnessing male peer networks to enhance engagement with HIV prevention: A large-scale cluster randomized trial to increase HIV self-testing and PrEP uptake among men in Eastern Zimbabwe | 000 | 2 | NIH | 5/6/2024 | $482,125 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW012302 | Longitudinal microbiome-host interactions and clinical outcomes in drug-resistant tuberculosis patients | 000 | 3 | NIH | 6/20/2024 | $89,609 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01HD102050 | MECHANISMS LEADING TO ADVERSE BIRTH OUTCOMES IN SOUTH AFRICAN HIV-INFECTED WOMEN | 002 | 5 | NIH | 6/5/2024 | $3,252 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01HD102050 | MECHANISMS LEADING TO ADVERSE BIRTH OUTCOMES IN SOUTH AFRICAN HIV-INFECTED WOMEN | 001 | 5 | NIH | 5/7/2024 | $19,231 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01HD102050 | MECHANISMS LEADING TO ADVERSE BIRTH OUTCOMES IN SOUTH AFRICAN HIV-INFECTED WOMEN | 001 | 5 | NIH | 5/7/2024 | $10,026 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01HD102050 | MECHANISMS LEADING TO ADVERSE BIRTH OUTCOMES IN SOUTH AFRICAN HIV-INFECTED WOMEN | 000 | 5 | NIH | 3/27/2024 | $173,079 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01HD102050 | MECHANISMS LEADING TO ADVERSE BIRTH OUTCOMES IN SOUTH AFRICAN HIV-INFECTED WOMEN | 000 | 5 | NIH | 3/27/2024 | $119,505 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI152109 | Nanoparticle-based host-directed therapies for eradication of Mycobacterium tuberculosis | 000 | 5 | NIH | 4/18/2024 | $111,011 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI152109 | Nanoparticle-based host-directed therapies for eradication of Mycobacterium tuberculosis | 000 | 5 | NIH | 4/18/2024 | $192,405 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI152119 | Urine tenofovir point-of-care test to identify patients in need of ART adherence support | 000 | 5 | NIH | 7/29/2024 | $147,644 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI152119 | Urine tenofovir point-of-care test to identify patients in need of ART adherence support | 000 | 5 | NIH | 7/29/2024 | $178,498 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | R01AI136837 | Adaptation, fitness and resistance in rifampicin-resistant M. tuberculosis | 000 | 5 | NIH | 6/20/2024 | $131,599 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW010547 | Africa Center for Biostatistical Excellence: Expanding biostatistical leadership for HIV/AIDS and TB Research | 000 | 8 | NIH | 4/15/2024 | $247,464 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | D43TW010547 | Africa Center for Biostatistical Excellence: Expanding biostatistical leadership for HIV/AIDS and TB Research | 000 | 8 | NIH | 4/15/2024 | $50,000 |
| | 2024 | 2024 | STELLENBOSCH UNIVERSITY | ADMINISTRATION BUILDING B, VICTORIA ST | STELLENBOSCH | | | | ZAF | K43TW011028 | The long-term consequences of pulmonary tuberculosis and respiratory viruses on lung health in young South African children | 000 | 5 | NIH | 8/2/2024 | $112,523 |
|
